-
Product Insights
IgA Nephropathy (Berger’s Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
IgA Nephropathy Clinical Trial Report Overview A total of 298 IgA Nephropathy clinical trials were conducted as of January 2024. The IgA Nephropathy clinical trial report provides a comprehensive understanding of the IgA Nephropathy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
IgA Nephropathy (Berger’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘IgA Nephropathy (Berger's Disease) - Drugs In Development, 2023’, provides an overview of the IgA Nephropathy (Berger's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Membranous Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranous Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Membranous Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) - Drugs In Development, 2023’, provides an overview of the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) - Drugs In Development, 2023’, provides an overview of the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Focal Segmental Glomerulosclerosis (FSGS) - Drugs In Development, 2023’, provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Sector Analysis
IgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
IgA Nephropathy Competitive Analysis Report Overview IgA Nephropathy (Berger's disease) is an autoimmune disease that occurs when clumps of antibodies are deposited in the kidneys, causing inflammation and kidney damage. Clumps of IgA and other antibodies damage the glomeruli, tiny blood vessels in the kidneys that filter blood, causing the kidneys to leak blood and protein into the urine. The damage may also lead to scarring of the nephrons, the filtering units where the glomeruli are located. Key Mechanism of...